bioMérieux S.A.
bioMérieux S.A. Fundamental Analysis
bioMérieux S.A. (BMXXY) shows weak financial fundamentals with a PE ratio of 38.88, profit margin of 9.17%, and ROE of 9.29%. The company generates $4.1B in annual revenue with moderate year-over-year growth of 8.31%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 53.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BMXXY's fundamental strength across five key dimensions:
Efficiency Score
WeakBMXXY struggles to generate sufficient returns from assets.
Valuation Score
ModerateBMXXY shows balanced valuation metrics.
Growth Score
ExcellentBMXXY delivers strong and consistent growth momentum.
Financial Health Score
ExcellentBMXXY maintains a strong and stable balance sheet.
Profitability Score
WeakBMXXY struggles to sustain strong margins.
Key Financial Metrics
Is BMXXY Expensive or Cheap?
P/E Ratio
BMXXY trades at 38.88 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BMXXY's PEG of -3.65 indicates potential undervaluation.
Price to Book
The market values bioMérieux S.A. at 3.74 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 14.81 times EBITDA. This signals the market has high growth expectations.
How Well Does BMXXY Make Money?
Net Profit Margin
For every $100 in sales, bioMérieux S.A. keeps $9.17 as profit after all expenses.
Operating Margin
Core operations generate 12.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.29 in profit for every $100 of shareholder equity.
ROA
bioMérieux S.A. generates $7.04 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
bioMérieux S.A. produces operating cash flow of $779.76M, showing steady but balanced cash generation.
Free Cash Flow
bioMérieux S.A. generates strong free cash flow of $434.97M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.37 in free cash annually.
FCF Yield
BMXXY converts 3.02% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.88
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.65
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.74
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.53
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.27
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How BMXXY Stacks Against Its Sector Peers
| Metric | BMXXY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.88 | 29.45 | Worse (Expensive) |
| ROE | 9.29% | 779.00% | Weak |
| Net Margin | 9.17% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.13 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 2.27 | 4.65 | Strong Liquidity |
| ROA | 7.04% | -19344.00% (disorted) | Weak |
BMXXY outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews bioMérieux S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
49.47%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
59.15%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
64.34%
Industry Style: Defensive, Growth, Innovation
High Growth